During 2017 and 2018, drug makers raised prices on seven widely used medicines by large amounts, but without any new clinical evidence to justify the increases, leading patients and insurers in the U.S. to spend an added $5.1 billion, according to a new analysis.

For instance, AbbVie (ABBV) boosted the price on its best-selling Humira rheumatoid arthritis treatment by 15.9%, after accounting for estimated rebates and other discounts, which caused Americans to spend an extra $1.86 billion than they would have if the company had not raised the price during that two-year period.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Kudos to author capturing the wide range of perspectives on this report. I think a broader discussion, however, is warranted about that fact that these are businesses, which will raise prices on successful products to offset the costs of failing or unprofitable products. There is no analysis in ICER report of the company-wide increases on drugs — they do seem to cherrypick the best sellers. That’s like saying Apple has exorbitantly raised prices on the iPhone without considering that those prices increases covered the costs of failed investments in other divisions (remember iTunes U anyone?).

    For whatever reason, we seem to ignore the basic economics amid this tough debate about drug prices. These drugs work and so demand goes up, that would suggest price increases commensurate with demand go up. We need to focus on increasing supply (through competition, generics/biosims, etc.), and not continue fighting market forces which govern far more than just the health sector.

  • While Mr Fein is insightful as always, his closing line is… perhaps truncated. Yes, “The cost of things goes up.” Granted, but not by that much.
    May I observed that point is the apparently excessive price increases.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy